NEXGEL, INC. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
NexGel reported Q2 2026 revenue of $3.69 million and net loss of $2.87 million (ending June 30, 2026). The company completed its Celularity acquisition in mid-April 2026, forming the BioNX Surgical division, but integration and revenue ramp proceeded slower than anticipated due to ongoing supply chain constraints, resulting in approximately $795,000 backlog. Non-recurring charges included $756,554 in intangible asset amortization, $273,710 in transaction costs, and $144,495 for SilverSeal inventory recall to support hospital market launch. Failed shareholder vote on authorized shares and reverse split (due to broker non-votes) will be re-solicited as standalone proposals by late September 2026.
Why this rating
Material acquisition integration underway with material revenue miss and supply chain drag; $795K backlog significant vs. $11M market cap; shareholder governance failure requires remediation but address is planned.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.